Clinical Report: Twenty-Five Years of Progress in Cancer

Overview

Since 2000, cancer care has significantly evolved with the introduction of 11 new types of therapies and over 100 distinct new medicines, including CAR T-cell and radioligand therapies. Ongoing research continues to enhance treatment options and improve patient outcomes.

Background

The evolution of cancer treatment is crucial as it directly impacts patient survival and quality of life. Advances in cancer therapies have transformed the landscape of oncology, moving beyond traditional methods like chemotherapy and radiation. Continuous research and clinical trials are essential to further improve therapeutic options and patient care.

Data Highlights

Since 2000, there have been 11 new types of cancer therapies approved by the FDA, with over 100 distinct new medicines now available for cancer treatment.

Key Findings

• New therapies include CAR T-cell therapy and radioligand therapy, expanding treatment options beyond traditional methods.
• In 2025, the FDA approved over a dozen new cancer drugs, including Belzutifan for kidney cancer and Pembrolizumab for head and neck cancer.
• Dana-Farber has established the Center for RAS Therapeutics to develop new RAS-targeted therapies.
• Novel classes of medicines, such as NK cell therapies and personalized cancer vaccines, are currently in clinical trials.
• Clinical trials are essential for testing new combinations of existing therapies to enhance patient benefits.

Clinical Implications

Healthcare professionals should stay informed about the latest advancements in cancer therapies to provide optimal care for patients. The integration of novel treatments and ongoing clinical trials can lead to improved patient outcomes and survival rates, emphasizing the need for continuous education and adaptation.

Conclusion

The progress in cancer treatment over the past 25 years highlights the importance of continued research and innovation in oncology. These advancements are crucial for enhancing the quality of life and survival rates for cancer patients.

References

1. The ASCO Post, 2014 -- Videos Tell Stories of 50 Years of Progress Against Cancer
2. The ASCO Post, 2014 -- Charting the Successes: CancerProgress.Net Chronicles More Than 50 Years of ASCO and Progress Against Cancer
3. The ASCO Post, 2024 -- AACR Cancer Progress Report Features Breakthroughs in Cancer Science and Persistent Inequities in Care KEY POINTS
4. The ASCO Post, 2025 -- AACR Cancer Progress Report 2025 Highlights Breakthroughs in Blood Cancers and How NIH Funding Uncertainty Threatens Advances
5. The ASCO Post, 2025 -- Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options
6. FDA, 2025 -- FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication
7. Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options - The ASCO Post
8. FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication | FDA
9. ASCO's Draft Guidelines for ctDNA Testing in Solid Tumors/Lymphoma Public Comment Period Open - Guideline Central